Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 4/20 | 0.52 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.51 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | CDK1 | P06493 | 1/20 | 0.40 |
| ▸ | MYT1 | Q01538 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
| ▸ | SPR | P35270 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.38 |
| ▸ | PARP1 | P09874 | 2/20 | 0.38 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | MTOR | P42345 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22054806 | 0.85 | DPP4 (0.50) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL25937534 | 0.84 | DPP4 (0.55) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL12332202 | 0.82 | NAMPT (0.48) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL22054673 | 0.81 | DPP4 (0.61) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL21555894 | 0.80 | DPP4 (0.55) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL30980046 | 0.80 | NAMPT (0.49) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL25428013 | 0.80 | DPP4 (0.48) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL22977583 | 0.79 | DPP4 (0.49) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL12208897 | 0.78 | NAMPT (0.45) | DPP4DPP8NOTUMNAMPTCDK1 | |
| SCHEMBL20097551 | 0.78 | NAMPT (0.48) | DPP4DPP8NOTUMNAMPTCDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2780337-B1 | SUBSTITUTED CYCLOPROPYL COMPOUNDS USEFUL AS GPR119 AGONISTS | MERCK SHARP & DOHME (US) | 2017-12-20 | — | — | EP | disclosed |
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SATORI PHARMACEUTICALS, INC. (US) | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130060013-A1 | Compounds useful for treating neurodegenerative disorders | SNCA, HTT, CLN6 | DPP4 1127/4885DPP8 2071/4885NOTUM 1421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.